Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100 - PubMed (original) (raw)
. 1996 Dec 1;157(11):5027-33.
Affiliations
- PMID: 8943411
Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100
J C Skipper et al. J Immunol. 1996.
Abstract
Human CD8+ CTL recognize peptides bound to class I MHC molecules on the surface of melanoma cells. Several peptides derived from melanocyte lineage-specific proteins have been identified as epitopes for HLA-A2 restricted melanoma-reactive CTL. Because less than half of melanoma patients express HLA-A2, it is important to identify CTL epitopes restricted by other common MHC molecules including HLA-A1 and -A3. We have generated HLA-A3-restricted human CTL that recognize one or more shared melanoma Ags. All of the melanomas recognized by one of these CTL lines express Pmel-17/gp100, and those that fail to express this Ag are not lysed. This CTL line also specifically recognizes the lymphoblastoid line C1R-A3 following infection with a recombinant vaccinia encoding the melanocyte lineage-specific protein Pmel-17/gp100. Thus, at least one Pmel-17/ gp100 peptide is an epitope for this CTL line. We have identified ALLAVGATK (Pmel-17/gp100 residues 17-25) as an epitope for this CTL line and have shown that it is naturally processed and presented by HLA-A3 on melanoma cells. A second HLA-A3-restricted melanoma-reactive CTL line recognizes at least one additional shared epitope. These findings suggest that cellular immune responses directed against multiple shared melanoma epitopes exist in the 20 to 25% of melanoma patients who express HLA-A3. In addition, immunotherapy directed against Pmel-17/gp100 and other shared melanoma Ags may be useful in a large subset of these patients.
Similar articles
- Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Kawakami Y, et al. J Immunol. 1998 Dec 15;161(12):6985-92. J Immunol. 1998. PMID: 9862734 - Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.
Kawakami Y, Rosenberg SA. Kawakami Y, et al. Int Rev Immunol. 1997;14(2-3):173-92. doi: 10.3109/08830189709116851. Int Rev Immunol. 1997. PMID: 9131386 Review. - New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines.
Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. Maeurer MJ, et al. Melanoma Res. 1996 Feb;6(1):11-24. doi: 10.1097/00008390-199602000-00003. Melanoma Res. 1996. PMID: 8640065 Review.
Cited by
- Innovations Toward Immunopeptidomics.
Abelin JG, Cox AL. Abelin JG, et al. Mol Cell Proteomics. 2024 Sep;23(9):100823. doi: 10.1016/j.mcpro.2024.100823. Epub 2024 Jul 31. Mol Cell Proteomics. 2024. PMID: 39095021 Free PMC article. Review. - A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, Grosh WW, Varhegyi N, Smolkin ME, Smith KT, Galeassi NV, Deacon DH, Gaughan EM, Slingluff CL Jr. Melssen MM, et al. J Immunother Cancer. 2019 Jun 27;7(1):163. doi: 10.1186/s40425-019-0625-x. J Immunother Cancer. 2019. PMID: 31248461 Free PMC article. Clinical Trial. - Immune targets and neoantigens for cancer immunotherapy and precision medicine.
Wang RF, Wang HY. Wang RF, et al. Cell Res. 2017 Jan;27(1):11-37. doi: 10.1038/cr.2016.155. Epub 2016 Dec 27. Cell Res. 2017. PMID: 28025978 Free PMC article. Review. - Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.
Hu Y, Petroni GR, Olson WC, Czarkowski A, Smolkin ME, Grosh WW, Chianese-Bullock KA, Slingluff CL Jr. Hu Y, et al. Cancer Immunol Immunother. 2014 Aug;63(8):779-86. doi: 10.1007/s00262-014-1551-x. Epub 2014 Apr 23. Cancer Immunol Immunother. 2014. PMID: 24756419 Free PMC article. - Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
Wang HY, Wang RF. Wang HY, et al. Adv Immunol. 2012;114:151-76. doi: 10.1016/B978-0-12-396548-6.00006-8. Adv Immunol. 2012. PMID: 22449781 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous